ATE268813T1 - Vektoren der alphavirus cdna - Google Patents

Vektoren der alphavirus cdna

Info

Publication number
ATE268813T1
ATE268813T1 AT95914666T AT95914666T ATE268813T1 AT E268813 T1 ATE268813 T1 AT E268813T1 AT 95914666 T AT95914666 T AT 95914666T AT 95914666 T AT95914666 T AT 95914666T AT E268813 T1 ATE268813 T1 AT E268813T1
Authority
AT
Austria
Prior art keywords
present
cdna
polynucleotide molecules
animal
desired products
Prior art date
Application number
AT95914666T
Other languages
English (en)
Inventor
Peter Liljestroem
Henrik Garoff
Original Assignee
Bioption Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20393495&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE268813(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bioption Ab filed Critical Bioption Ab
Application granted granted Critical
Publication of ATE268813T1 publication Critical patent/ATE268813T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/123—Hepatitis delta
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/52—Vector systems having a special element relevant for transcription encoding ribozyme for self-inactivation
AT95914666T 1994-03-31 1995-03-30 Vektoren der alphavirus cdna ATE268813T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9401091A SE9401091D0 (sv) 1994-03-31 1994-03-31 Alphavirus cDNA vectors
PCT/SE1995/000343 WO1995027044A1 (en) 1994-03-31 1995-03-30 ALPHAVIRUS cDNA VECTORS

Publications (1)

Publication Number Publication Date
ATE268813T1 true ATE268813T1 (de) 2004-06-15

Family

ID=20393495

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95914666T ATE268813T1 (de) 1994-03-31 1995-03-30 Vektoren der alphavirus cdna

Country Status (12)

Country Link
US (1) US6566093B1 (de)
EP (1) EP0753053B1 (de)
JP (1) JPH09511143A (de)
AT (1) ATE268813T1 (de)
AU (1) AU699384B2 (de)
CA (1) CA2184261A1 (de)
DE (1) DE69533130T2 (de)
DK (1) DK0753053T3 (de)
ES (1) ES2223051T3 (de)
FI (1) FI963860A (de)
SE (1) SE9401091D0 (de)
WO (1) WO1995027044A1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US6451592B1 (en) 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US6458560B1 (en) 1996-04-05 2002-10-01 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US5811407A (en) 1997-02-19 1998-09-22 The University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow
US6432699B1 (en) 1997-03-28 2002-08-13 New York University Viral vectors having chimeric envelope proteins containing the IgG-binding domain of protein A
NZ500740A (en) 1997-05-13 2001-02-23 Univ North Carolina Recombinant lentivirus-based gene transfer vectors comprising 3 vectors from Equine Infectious Anemia Virus (EIAV)
FI110323B (fi) 1997-06-02 2002-12-31 Timo Korpela Rekombinanttikonstrukti geenin ilmentämisen lisäämiseksi kasveissa
US20030180257A1 (en) * 1997-11-14 2003-09-25 Mark Parrington Alphavirus vectors for paramyxovirus vaccines
DE69835369T2 (de) * 1997-11-14 2007-08-23 Sanofi Pasteur Ltd., Toronto Alphavirus-vektoren
EP1707633A1 (de) * 1997-11-14 2006-10-04 Sanofi Pasteur Limited Alphavirus-Vektoren als Impfstoffe gegen Paramyxovirus
US8647864B2 (en) 1999-04-14 2014-02-11 Novartis Ag Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
CA2721011A1 (en) 1999-10-22 2001-05-03 Aventis Pasteur Limited Modified gp100 and uses thereof
EP1232264B1 (de) 1999-11-18 2009-10-21 Novartis Vaccines and Diagnostics, Inc. Menschliches fgf-21 gen und genexpressionsprodukte
AU2001249125A1 (en) 2000-03-08 2001-09-17 Chiron Corporation Human fgf-23 gene and gene expression products
ATE346925T1 (de) 2000-05-10 2006-12-15 Sanofi Pasteur Ltd Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
ES2312447T3 (es) 2000-05-31 2009-03-01 Novartis Vaccines And Diagnostics, Inc. Procedimiento para la purificacion de particulas de replicon alfavirus.
AU2001290642A1 (en) 2000-09-07 2002-03-22 University Of North Carolina At Chapel Hill Vectors derived from south african arbovirus no. 86
AU2002258631B2 (en) * 2001-03-27 2007-05-17 New York University Tumor therapy with alphavirus-based and high affinity laminin receptor-targeted vectors
AU2002258728A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
WO2002081639A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
AU2002305151A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
DE60233061D1 (de) 2001-09-06 2009-09-03 Alphavax Inc Alphavirus replikon-vektorsysteme
KR100981471B1 (ko) 2002-03-15 2010-09-10 더 큐레이터스 오브 더 유니버시티 오브 미주리 효소 활성이 감소된 형별불능 헤모필러스 인플루엔자의ｐ4 변형 단백질
DE60315628T2 (de) 2002-04-09 2008-06-05 Sanofi Pasteur Ltd., Toronto Modifizierte cea nucleinsäure und expressionsvektoren
US7244565B2 (en) 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
US20050221493A1 (en) * 2002-12-04 2005-10-06 Crucell Holland B.V. Recombinant virus production for the manufacturing of vaccines
JP4991108B2 (ja) 2002-12-13 2012-08-01 アルファバックス，インコーポレイティド 多抗原性アルファウイルス・レプリコン粒子及び方法
AU2003297041B2 (en) 2002-12-13 2009-02-26 Alphavax, Inc. Alphavirus particles and methods for preparation
AU2004223477B2 (en) 2003-03-20 2009-03-26 Alphavax, Inc. Improved alphavirus replicons and helper constructs
DK1651666T3 (da) 2003-07-11 2009-08-31 Alphavax Inc Alfavirus-baserede cytomegalovirusvacciner
US7910093B2 (en) 2003-08-19 2011-03-22 New York University Method for detecting cancer cells and monitoring cancer therapy
ATE506444T1 (de) * 2003-10-08 2011-05-15 Sanofi Pasteur Ltd Modifizierter cea/b7-vektor
JP2007535329A (ja) * 2004-04-29 2007-12-06 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 細胞接着性を増強する方法および組成物
AU2005245956B2 (en) 2004-05-18 2011-05-19 Alphavax, Inc. TC-83-derived alphavirus vectors, particles and methods
ES2292271B1 (es) * 2004-05-20 2009-02-16 Proyecto De Biomedicina Cima, S.L. Un vector hibrido adenovirus-alfavirus para la administracion eficaz y expresion de genes terapeuticos en celulas tumorales.
FI20040704A0 (fi) * 2004-05-21 2004-05-21 Ari Hinkkanen Replikatiivisen viruksen tai sen rekombinantin käyttö terapiassa
AU2005327198B2 (en) 2004-07-09 2011-03-31 University Of North Carolina At Chapel Hill Viral adjuvants
AU2006302794B2 (en) 2005-02-15 2011-08-04 Children's Hospital, Inc. New live virus vaccines
US7303898B2 (en) * 2005-03-29 2007-12-04 New York University Defective sindbis viral vectors
FR2887259B1 (fr) * 2005-06-21 2007-09-14 Agronomique Inst Nat Rech CONSTRUCTION D'ADNc D'ALPHAVIRUS DE SALMONIDES
AU2008266807B2 (en) 2007-06-21 2012-08-16 Alphavax, Inc. Promoterless cassettes for expression of alphavirus structural proteins
US9474800B2 (en) * 2008-05-23 2016-10-25 Fit Biotech Oy Expression vector encoding alphavirus replicase and the use thereof as immunological adjuvant
CL2008002322A1 (es) * 2008-08-07 2009-06-05 Univ Concepcion Formulacion farmaceutica veterinaria que comprende un sistema vectorial viral constituido por una particula recombinante de arn que codifica una cu/zn superoxido dismutasa de la bacteria patogena de bovinos brucella abortus, y al menos un alfavirus arn perteneciente a la familia del virus semliki forest (sfv), util como vacuna.
WO2011038063A1 (en) 2009-09-28 2011-03-31 The Trustees Of The University Of Pennsylvania Method of diagnosing and treating interstitial cystitis
EP2698635A3 (de) 2010-12-01 2014-05-28 The University Of North Carolina At Chapel Hill Verfahren und Zusammensetzungen zum Targeting auf Stellen neovaskulären Wachstums
EP4010350A4 (de) 2019-08-09 2023-11-22 Nutcracker Therapeutics, Inc. Verfahren und vorrichtungen zur herstellung für die entfernung von material aus einer therapeutischen zusammensetzung
CN115197964A (zh) * 2021-04-12 2022-10-18 华南农业大学 一种改进型pSFV1载体及其制备方法与应用
CN113549652A (zh) * 2021-07-21 2021-10-26 华农（肇庆）生物产业技术研究院有限公司 SFV-helper质粒、pSFVCs-LacZ病毒样颗粒及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217879A (en) * 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
SE9003978D0 (sv) * 1990-12-13 1990-12-13 Henrik Garoff Dna expressionssystem baserade paa ett virus replikon
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
DE69435224D1 (de) 1993-09-15 2009-09-10 Novartis Vaccines & Diagnostic Rekombinante Alphavirus-Vektoren

Also Published As

Publication number Publication date
SE9401091D0 (sv) 1994-03-31
JPH09511143A (ja) 1997-11-11
ES2223051T3 (es) 2005-02-16
DE69533130T2 (de) 2005-07-07
FI963860A0 (fi) 1996-09-27
FI963860A (fi) 1996-09-27
AU2155795A (en) 1995-10-23
DK0753053T3 (da) 2004-10-11
US6566093B1 (en) 2003-05-20
CA2184261A1 (en) 1995-10-12
DE69533130D1 (de) 2004-07-15
EP0753053B1 (de) 2004-06-09
EP0753053A1 (de) 1997-01-15
WO1995027044A1 (en) 1995-10-12
AU699384B2 (en) 1998-12-03

Similar Documents

Publication Publication Date Title
ATE268813T1 (de) Vektoren der alphavirus cdna
IT7927940A0 (it) Estrattore chirurgico per asportare corpi estranei che si trovano nelle vie naturali del corpo umano, come calcoli e simili.
ATE485371T1 (de) Varianten des menschlichen koagulationsfaktors vii
DE69034018D1 (de) Kombinierte verwendung von hyaluronsäure und therapeutischen wirkstoffen zur verbesserung des therapeutischen effekts
ES557100A0 (es) Un metodo de produccion de un polipeptido con actividad de proteina c humana en una celula huesped
DE69535376D1 (de) Expressionsvektor des alphavirus
EP0365598A4 (en) Therapeutic antimicrobial polypeptides, their use and methods for preparation
ATE192500T1 (de) Rekombinante viren vektoren zur expression in muskelzellen
FI844510L (fi) Ensym-resistenta immunsystemet modulerande peptider.
ATE230985T1 (de) Verwendung von xanthophyllen zur herstellung von arzneimitteln zur verbesserung der muskel- funktionsdauer oder zur behandlung von muskelstörungen oder erkrankungen
ATE389724T1 (de) Menschliche dnase i hyperaktive varianten
MXPA03001984A (es) Variantes de factor vii de coagulacion humano.
TW200407425A (en) Human coagulation factor VII polypeptides
DE69130679D1 (de) Die herstellung von zusammensetzungen zur behandlung von krankheiten der zellproliferation
ATE222101T1 (de) Verwendung von selegilin oder desmethylselegilin zur behandlung von wunden, verbrennungen und hautschäden
ES8704184A1 (es) Un metodo para producir un polipeptidos similar a lipocortina humana.
GB2030043B (en) Injectable composition for the treatment of helminthiasis and clostridial diseases in animals
Wodzicka-Tomaszewska et al. Interactions between stress and boar stimulation in induction of puberty in gilts.
Nikitina Effect of noradrenaline and potassium ions on the electrical and contractile activity of coronary artery smooth muscle cells
DK0556395T3 (da) Hidtil unkendt cytokin
UA10281C2 (uk) Спосіб отримання речовини для лікування захворювань підшлункової залози
KR910016339A (ko) Pp4-델타, 이의 제조방법 및 용도
IT8220835A0 (it) Preparazione di soluzioni iniettabili di actinina impiegabili nella terapia umana come antalgico per il trattamento del dolore da neoplasie ed altre affezioni.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0753053

Country of ref document: EP